The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements

Immunity

Volumn 44, Issue 2, 2016, Pages 406-421

  Procaccini, Claudio ^a   Carbone, Fortunata ^a   Di Silvestre, Dario ^a   Brambilla, Francesca ^a   De Rosa, Veronica ^a,b   Galgani, Mario ^a   Faicchia, Deriggio ^c   Marone, Gianni ^c   Tramontano, Donatella ^c   Corona, Marco ^d   Alviggi, Carlo ^c   Porcellini, Antonio ^c   La Cava, Antonio ^e   Mauri, Pierluigi ^a,f   Matarese, Giuseppe ^a,c  

^a CNR   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

Conventional T cells; Immune Tolerance; Metabolism; Proteomic Analysis; Regulatory T cells

Indexed keywords

ACONITASE 2; ACONITATE HYDRATASE; ALDOLASE A; APOLIPOPROTEIN B100; APOLIPOPROTEIN E; CITRATE SYNTHASE; ELECTRON TRANSFERRING FLAVOPROTEIN; ENOLASE; ENOLASE 1; FATTY ACID; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 7 RECEPTOR; ISOCITRATE DEHYDROGENASE 2; MALATE DEHYDROGENASE; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE KINASE 1; PHOSPHOGLYCERATE MUTASE; PHOSPHOGLYCERATE MUTASE 1; PHOSPHOGLYCERATE MUTASE 2; SUCCINATE DEHYDROGENASE; TRANSALDOLASE; TRANSALDOLASE 1; TRANSCRIPTION FACTOR FOXP3; UBIQUINOL CYTOCHROME C REDUCTASE; UBIQUINOL CYTOCHROME C REDUCTASE 2; UBIQUINOL CYTOCHROME C REDUCTASE I; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 1; VOLTAGE DEPENDENT ANION CHANNEL 2; VOLTAGE DEPENDENT ANION CHANNEL 3; CD4 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTOME;

ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL COMPARTMENTALIZATION; CELL ISOLATION; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CITRIC ACID CYCLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SYNTHESIS; DOWN REGULATION; EX VIVO STUDY; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIPID METABOLISM; MITOCHONDRIAL PERMEABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEOMICS; RESPIRATORY CHAIN; T LYMPHOCYTE; UPREGULATION; CELL CULTURE; IMMUNOLOGY; METABOLISM; OXIDATION REDUCTION REACTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD4; CELL PROLIFERATION; CELLS, CULTURED; FATTY ACIDS; FORKHEAD TRANSCRIPTION FACTORS; GLUCOSE; GLYCOLYSIS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; OXIDATION-REDUCTION; PROTEOMICS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTOME;

EID: 84958624127     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.01.028     Document Type: Article

References (41)

1. Bellemore S.M., Nikoopour E., Au B.C., Krougly O., Lee-Chan E., Haeryfar S.M., Singh B. Anti-atherogenic peptide Ep1.B derived from apolipoprotein E induces tolerogenic plasmacytoid dendritic cells. Clin. Exp. Immunol. 2014, 177:732-742.
2. Berod L., Friedrich C., Nandan A., Freitag J., Hagemann S., Harmrolfs K., Sandouk A., Hesse C., Castro C.N., Bähre H., et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat. Med. 2014, 20:1327-1333.
3. Bluestone J.A., Mackay C.R., O'Shea J.J., Stockinger B. The functional plasticity of T cell subsets. Nat. Rev. Immunol. 2009, 9:811-816.
4. Bluestone J.A., Buckner J.H., Fitch M., Gitelman S.E., Gupta S., Hellerstein M.K., Herold K.C., Lares A., Lee M.R., Li K., et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 2015, 7:315ra189.
5. Brambilla F., Lavatelli F., Di Silvestre D., Valentini V., Rossi R., Palladini G., Obici L., Verga L., Mauri P., Merlini G. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012, 119:1844-1847.
6. Burchill M.A., Yang J., Vogtenhuber C., Blazar B.R., Farrar M.A. IL-receptor β-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J. Immunol. 2007, 178:280-290.
7. Carbone F., De Rosa V., Carrieri P.B., Montella S., Bruzzese D., Porcellini A., Procaccini C., La Cava A., Matarese G. Regulatory T cell proliferative potential is impaired in human autoimmune disease. Nat. Med. 2014, 20:69-74.
8. Cheng G., Yu A., Malek T.R. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol. Rev. 2011, 241:63-76.
9. Cheng G., Yu A., Dee M.J., Malek T.R. IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development. J. Immunol. 2013, 190:1567-1575.
10. Cheng S.C., Quintin J., Cramer R.A., Shepardson K.M., Saeed S., Kumar V., Giamarellos-Bourboulis E.J., Martens J.H., Rao N.A., Aghajanirefah A., et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 2014, 345:1250684.
11. De Rosa V., Procaccini C., Calì G., Pirozzi G., Fontana S., Zappacosta S., La Cava A., Matarese G. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007, 26:241-255.
12. De Rosa V., Galgani M., Porcellini A., Colamatteo A., Santopaolo M., Zuchegna C., Romano A., De Simone S., Procaccini C., La Rocca C., et al. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat. Immunol. 2015, 16:1174-1184.
13. Gerriets V.A., Kishton R.J., Nichols A.G., Macintyre A.N., Inoue M., Ilkayeva O., Winter P.S., Liu X., Priyadharshini B., Slawinska M.E., et al. Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J. Clin. Invest. 2015, 125:194-207.
14. Khazaie K., von Boehmer H. The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin. Cancer Biol. 2006, 16:124-136.
15. Kohrt H.E., Pillai A.B., Lowsky R., Strober S. NKT cells, Treg, and their interactions in bone marrow transplantation. Eur. J. Immunol. 2010, 40:1862-1869.
16. Li L., Godfrey W.R., Porter S.B., Ge Y., June C.H., Blazar B.R., Boussiotis V.A. CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 2005, 106:3068-3073.
17. Long S.A., Cerosaletti K., Bollyky P.L., Tatum M., Shilling H., Zhang S., Zhang Z.Y., Pihoker C., Sanda S., Greenbaum C., Buckner J.H. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010, 59:407-415.
18. Luo C.T., Li M.O. Transcriptional control of regulatory T cell development and function. Trends Immunol. 2013, 34:531-539.
19. Macintyre A.N., Gerriets V.A., Nichols A.G., Michalek R.D., Rudolph M.C., Deoliveira D., Anderson S.M., Abel E.D., Chen B.J., Hale L.P., Rathmell J.C. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 2014, 20:61-72.
20. Maciolek J.A., Pasternak J.A., Wilson H.L. Metabolism of activated T lymphocytes. Curr. Opin. Immunol. 2014, 27:60-74.
21. MacIver N.J., Michalek R.D., Rathmell J.C. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 2013, 31:259-283.
22. Mauri P., Scarpa A., Nascimbeni A.C., Benazzi L., Parmagnani E., Mafficini A., Della Peruta M., Bassi C., Miyazaki K., Sorio C. Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J. 2005, 19:1125-1127.
23. Michalek R.D., Gerriets V.A., Jacobs S.R., Macintyre A.N., MacIver N.J., Mason E.F., Sullivan S.A., Nichols A.G., Rathmell J.C. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 2011, 186:3299-3303.
24. Min W.P., Zhou D., Ichim T.E., Strejan G.H., Xia X., Yang J., Huang X., Garcia B., White D., Dutartre P., et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J. Immunol. 2003, 170:1304-1312.
25. Nilsson J., Björkbacka H., Fredrikson G.N. Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential. Curr. Opin. Lipidol. 2012, 23:422-428.
26. Painter M.W., Davis S., Hardy R.R., Mathis D., Benoist C. Transcriptomes of the B and T lineages compared by multiplatform microarray profiling. J. Immunol. 2011, 186:3047-3057. Immunological Genome Project Consortium.
27. - effector T cells. Int. Immunol. 2008, 20:421-431.
28. Procaccini C., Matarese G. Regulatory T cells, mTOR kinase, and metabolic activity. Cell. Mol. Life Sci. 2012, 69:3975-3987.
29. Procaccini C., De Rosa V., Galgani M., Abanni L., Calì G., Porcellini A., Carbone F., Fontana S., Horvath T.L., La Cava A., Matarese G. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 2010, 33:929-941.
30. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
31. Sauer S., Bruno L., Hertweck A., Finlay D., Leleu M., Spivakov M., Knight Z.A., Cobb B.S., Cantrell D., O'Connor E., et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. USA 2008, 105:7797-7802.
32. Schmidl C., Hansmann L., Lassmann T., Balwierz P.J., Kawaji H., Itoh M., Kawai J., Nagao-Sato S., Suzuki H., Andreesen R., et al. The enhancer and promoter landscape of human regulatory and conventional T-cell subpopulations. Blood 2014, 123:e68-e78. FANTOM consortium.
33. Tandon P., Gallo C.A., Khatri S., Barger J.F., Yepiskoposyan H., Plas D.R. Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency. Proc. Natl. Acad. Sci. USA 2011, 108:2361-2365.
34. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., Piccirillo C.A., Salomon B.L., Bluestone J.A. Central role of defective interleukin-production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697.
35. Thornton A.M., Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998, 188:287-296.
36. Vowinkel T., Mori M., Krieglstein C.F., Russell J., Saijo F., Bharwani S., Turnage R.H., Davidson W.S., Tso P., Granger D.N., Kalogeris T.J. Apolipoprotein A-IV inhibits experimental colitis. J. Clin. Invest. 2004, 114:260-269.
37. Vukmanovic-Stejic M., Zhang Y., Cook J.E., Fletcher J.M., McQuaid A., Masters J.E., Rustin M.H., Taams L.S., Beverley P.C., Macallan D.C., Akbar A.N. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 2006, 116:2423-2433.
38. Vukmanovic-Stejic M., Agius E., Booth N., Dunne P.J., Lacy K.E., Reed J.R., Sobande T.O., Kissane S., Salmon M., Rustin M.H., Akbar A.N. The kinetics of CD4+Foxp3+ T cell accumulation during a human cutaneous antigen-specific memory response in vivo. J. Clin. Invest. 2008, 118:3639-3650.
39. Wilhelm A.J., Zabalawi M., Owen J.S., Shah D., Grayson J.M., Major A.S., Bhat S., Gibbs D.P., Thomas M.J., Sorci-Thomas M.G. Apolipoprotein A-modulates regulatory T cells in autoimmune LDLr-/-ApoA-I-/- mice. J. Biol. Chem. 2010, 285:36158-36169.
40. Zeng H., Yang K., Cloer C., Neale G., Vogel P., Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature 2013, 499:485-490.
41. Zheng Y., Manzotti C.N., Liu M., Burke F., Mead K.I., Sansom D.M. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J. Immunol. 2004, 172:2778-2784.